Issue 161

Vital report explores employment in the psychedelics industry

Psychedelics Today recently surveyed students and graduates of its 12-month intensive professional psychedelic certification programme, Vital, publishing its findings in The Emerging Psychedelic Workforce report.

David Drapkin, Director of Education at Psychedelics Today, discussed the findings, emphasising the growth of the industry and highlighting the significance of personal experience and motivations for entering the field, as well as the importance of education and awareness.

“The report shows that our future workforce is going to have a lot of diversity on multiple levels including racial and ethnic diversity and LGBTQ representation,” said Drapkin.

“The report shows that our future workforce is going to have a lot of diversity on multiple levels including racial and ethnic diversity and LGBTQ representation,” said Drapkin.

READ MORE

ANXIETY TREATED WITH PSYCHEDELIC DRUG IN PHASE 2B TRIAL

MindMed has announced that its psychedelic drug – MM-120 – has shown positive results in the treatment of generalised anxiety disorder in a Phase 2b trial.

The company has said that the trial met its primary endpoint, with results shoing a clinical response rate of 78% in 100 µg and 200 µg dose groups and a 50% clinical remission rate in the 100 µg dose group at Week Four.

Read More

DESIGNING NON-HALLUCINOGENIC PSYCHEDELIC TREATMENTS

The Medical College of Wisconsin (MCW) explores the topic of non-hallucinogenic psychedelic treatments that may accelerate research on mental health.

John McCorvy, assistant professor of cell biology, neurobiology and anatomy at MCW explains: “Hopefully in the future this will help increase study of these compounds if the hallucinogenic hurdles can be removed.”

Read More

BUSINESS AND INVESTMENT

Mydecine Innovations Group has announced it has received a Notice of Allowance from USPTO for its MYCO-005 compound.

Clearmind Medicine has announced it has regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2).

Cedar Clinical Research has been selected as one of multiple sites for Beckley Psytech’s Phase 2b clinical trial for Treatment Resistant Depression.

Tryp Therapeutics has announced the signing of a definitive agreement with Exopharm Limited, expecting to relist on the Australian Securities Exchange.

SCIENCE AND RESEARCH

The Journal of Military, Veteran and Family Health has dedicated its latest edition to psychedelics.

Technology Networks held an AMA with invited Dr Boris Heifets of Stanford School of Medicine on psychedelics.

Clinical trial results suggest that psilocybin may help people with cancer and major depression.

Ron Shore, Queen’s University, Ontario Research Scientist, explores psychedelic access for veterans in The Conversation.

REGULATION AND LEGISLATION

Congress has approved a defence spending bill that includes funding for psychedelic research to help treat active duty service members.

The EMA is set to host a multi-stakeholder workshop on psychedelics in April 2024 in Amsterdam to explore psychedelics in mental health.

A new study has shown strong bipartisan support for controlled psilocybin use as treatment or enhancement in a representative sample of Americans.

Provincetown, Massachusetts has voted to effectively decrminalise psilocybin through deprioritising such cases with the police, reports WBUR.

ARTICLES OF INTEREST

A new report from the UK Government shows the number of adults entering treatment for substance misuse from 2022 to 2023 was higher than the previous two years.

A new WHO/Europe report covering 40 countries on the continent has found that millions of people are still struggling to pay for health care, leading to people experiencing financial hardship.

Partner with us